Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Cancer Grand Challenges - AI-human collaborations in cancer

Cancer Grand Challenges

This is a new challenge, which we announced in March 2025. It is open for Expressions of Interest, with the successful team(s) being awarded up to £20m ($25m) to tackle it. Submissions are due by 18 June 2025.

Context

Cancer research continues to become more complex. Research questions increasingly require a wide range of expertise to address. Additionally, there is a growing volume and variety of data that spans scales from molecular data to epidemiological data. Furthermore, publications are increasing at an exponential rate making it more challenging to identify the most important new findings. However, recent advances in AI can help overcome these challenges. Large language models (LLMs) have been trained on vast quantities of text data, including scientific literature, and have shown high accuracy in answering scientific questions. Early work has begun to explore the use of LLMs to conduct scientific research.

This challenge aims to go beyond the ability of AI to extract information, make predictions, or conduct standard research tasks, making the leap to AI agents that can collaborate with humans to generate paradigm-shifting discoveries that advance cancer research. Agents are layers on top of LLMs that observe and collect information, provide input to the model, can conduct complex tasks, can have specific expertise, and can work together with other agents and humans.

Vision and impact

This challenge seeks to transform cancer research by advancing AI-driven tools and methods. It will enable the integration of the rapidly growing volume of cancer data and knowledge into AI-generated hypotheses. By fostering human-AI collaboration, this challenge aims to tackle complex cancer research questions, with the potential to reshape our understanding of the disease and identify new therapies.

Specialties

Cancer

Technology Development

Oncology

Eligibility Requirements

This challenge will require technological innovation to develop AI agents that can generate novel hypotheses that address important challenges in cancer research. The AI agents will also need to develop research plans to test these hypotheses that can be experimentally validated. Iterative cycles of experimental design and validation may be required. It is likely that multiple AI agents with different expertise and purposes will be required. It will also be important for there to be a human-in-the-loop to provide high level guidance and context that AI agents may lack.

The cancer research question that the AI agents are addressing should be complex and transdisciplinary and go beyond straightforward tasks and predictions. Of particular interest is cancer initiation and progression and the development of AI agents that can investigate the malignant conversion of precancerous lesions across tissues and identify novel therapeutics to prevent cancer initiation or progression in patients at risk.

This challenge will require close collaboration between AI researchers and cancer researchers and may also include machine learning specialists, data scientists, biologists, clinical researchers, and ethical advisors. Strategic academic-private partnerships are encouraged, with private partners contributing funds.

Sponsor Details

Sponsor Institute/Organizations: Cancer Grand Challenges

Sponsor Type: Corporate

Address: 2 Redman Place London, E20 1JQ

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity